Andrew D. Raeder is a founding partner of EMA Partners, LLC. For over 20 years, Mr. Raeder has advised middle market clients on numerous transactions in a variety of industries, from life sciences and medical devices, to specialty manufacturing, healthcare IT, and consumer products. Prior to co-founding EMA, Mr. Raeder was a founding partner of The Suffield Financial Group, LLC. During his tenure at SFG, and at Delta Capital Group, Mr. Raeder specialized in lower middle market merger and acquisition work.

For almost ten years, Mr. Raeder worked as a consultant to, and ultimately the President and CEO of two privately held companies: one in the consumer products industry, and the other a manufacturer of medical devices. He ultimately prepared and sold each company to larger competitors in their respective industries. Prior to that, Mr. Raeder worked as a business development consultant and financial analyst for several successful entrepreneurs, including the founders of the WD-40, Foto-Mat, and Smart Food companies. Mr. Raeder also performed due diligence support for mergers and acquisitions at Kirkland and Ellis, LLP. He worked on some of the largest transactions of the period, including Kraft Foods/Philip Morris, and Whirlpool/Roper. Other clients included Celestial Seasonings and Motorola Corporation.

Mr. Raeder graduated from Princeton University with a Bachelor of Arts in English, and holds an MBA from The University of Michigan. Mr. Raeder holds FINRA Series 79, Series 63 and Series 62 licenses.

Christopher B. Anderson has been associated with EMA Partners since 2003. In addition, Mr. Anderson has been a Managing Director for Blue Sage Advisors, Allied Business Group (a division of Mariner Wealth Advisors) and most recently The Scott Company/TSC Advisors.  Mr. Anderson began his M&A Investment Banking career at W.G.Nielson & Co. over 15 years ago, during which he has advised middle market clients on numerous transactions in a variety of industries, from consumer products (especially food and beverage), to energy services, distribution, specialty manufacturing, and business service clients.

Mr. Anderson holds a LL.M in Taxation from The University of Denver School of Law, a J.D. from California Western School of Law, and a B.A from The University of Michigan. Mr. Anderson holds FINRA Series 79 and Series 63 licenses.

Ms. Schrader’s background is in running companies and business divisions for nearly 20 years, with a focus in the life science sector for the last 10 years. Prior to joining the EMA team, she was President and CEO of the preclinical laboratory product company 3D Biomatrix, Inc. Before this she served as a senior business consultant for a medical device consulting firm for many years, after selling her own company in the retail sector.

Early in her career Ms. Schrader worked in economic development at the regional, state and national levels where she facilitated technology spinout collaborations between the U.S. government and the private sector and managed a federally-funded revolving loan fund. She holds a BA in business and economics from Olivet College and a product development certification from the University of Chicago Booth School of Business. She played college varsity basketball and was inducted into the Collegiate Athletic Hall of Fame.

Ms. Stump has more than 25 years of corporate financial planning and analysis experience in the biotechnology and food industries, which included various roles related to mergers and acquisitions. Prior to joining EMA, she served as an Associate Director of Finance for Amgen Corporation, where she supported the Research and Preclinical organization by providing valuation expertise for licensing and acquisition opportunities. Prior to Amgen, Ms. Stump was a Director of Financial Planning and Analysis for Immunex Corporation, a biotechnology company subsequently acquired by Amgen, for which she developed the valuation models to support the deal and was a key partner in the merger process. She began her career as a financial analyst working for Nalley's Fine Foods and participated in a number of divestiture and licensing agreements.

Ms. Stump holds an MBA from Pacific Lutheran University Graduate School of Business and a BA in Finance and International Business from the Honors College of Washington State University. Ms. Stump holds a FINRA Series 79 license.

At EMA, Mr. Tribble focuses on research and outreach, as well as financial analysis. He has worked extensively with clients in life sciences, healthcare and specialty manufacturing. Prior to EMA, Mr. Tribble was with NFP Insurance in Chicago, assisting the CFO with M&A integration analysis.

Mr. Tribble graduated from Miami University with a Bachelor of Science in Business. Mr. Tribble holds FINRA Series 79 and 63 licenses.

Ms. Webster has been with EMA Partners since inception, advising clients in a variety of industries, including life sciences, medical devices, specialty manufacturing, healthcare IT, and consumer products, for over 20 years. Prior to joining EMA, Ms. Webster was in consumer products marketing, working in brand management for Grand Metropolitan PLC and Diageo (LON:DGE) on a number of wine and spirits brands. Prior to Diageo, Ms. Webster was in financial services, administering 401(k) plans for Manufacturers National Bank of Detroit.

Ms. Webster holds a BA in Finance from Michigan State University, and an MBA in Marketing and General Management from The University of Michigan. Ms. Webster holds FINRA Series 79 and Series 63 licenses.

Tod O. White, Co-Founder Emeritus. During his tenure at EMA, Mr. White has advised clients on numerous transactions, primarily in the technology, life sciences and healthcare spaces.

Prior to founding EMA, Mr. White was General Counsel, Vice President and Secretary of Packard BioScience Company, where he was responsible for negotiating numerous acquisitions, divestitures, license agreements and financing deals. In addition, Mr. White oversaw the company's initial public offering (IPO) in 2000, and ultimately the merger of the company with PerkinElmer, Inc.

Prior to joining Packard, Mr. White was a transactional attorney at the Denver law firm of Jacobs, Chase, Frick, Kleinkopf & Kelley, LLC, where his practice included mergers, acquisitions, financings and securities work. Prior to that, Mr. White was a transactional attorney in the Denver office of Ballard, Spahr, Andrews & Ingersoll.

Mr. White holds a Bachelor of Arts degree from Hamilton College and his law degree from The University of Michigan Law School, where he graduated with honors.

David Olson, Advisor. David Olson is a serial entrepreneur who has co-founded six biotech start-ups, managed early-stage businesses, and authored business plans that generated substantial private and public funding.  Dr. Olson specializes in commercializing early stage life science technologies and has more than 20 years of experience in building life science companies, product development, intellectual property management, business development and venture financing.  Dr. Olson is currently a Mentor-in-Residence and Adjunct Faculty at the University of Michigan.  Previously he was CEO and co-founder of Swift Biosciences Inc. where he led the creation, funding and development of the company for six years.  During that time Swift invented and brought to market multiple new technologies for genetic analysis and Next Generation Sequencing.  Prior to Swift Biosciences, Dr. Olson was a founding member and senior executive of Accuri Cytometers (acquired by Becton Dickinson), which developed a successful product line of flow cytometers.  His other companies have focused on therapeutics and medical devices.  Dr. Olson received his PhD in Molecular Biology from Princeton University and completed a postdoctoral fellowship at the University of California, San Francisco.